The Corporate Transparency Act (“CTA”) was enacted in 2021 as part of the Anti-Money Laundering Act of 2020, requiring certain business entities (“Reporting Companies”) to report beneficial ownership information (“BOI”), and, for entities created or registered on or after January 1, 2024, information with respect to any individual who directly files the document creating the Reporting Company (“Company Applicant”), to the U.S. Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”).  McGuireWoods described the CTA’s requirements in a previous post.  

On November 7, 2023, FinCEN announced a final rule amending its beneficial ownership information (“BOI”) reporting requirements addressing the circumstances under which Reporting Companies may use an entity’s FinCEN Identifier instead of reporting the BOI of individuals owners of that entity.

The difficulties faced by healthcare provider consolidations could be temporary or they could indicate a long-term decline in the attractiveness of consolidation. Some challenges, like high debt and labor market imbalances, are temporary and don’t reflect the fundamental quality of the businesses involved.

On this episode of The Corner Series, McGuireWoods’ Geoff Cockrell is…

Notable litigation filed during October 2023 includes: California Land Acquisition and Development Inc. v. Eran Drori, et al.  Additionally, cryptocurrency and the potential for fraud surrounding the increasingly popular industry were on display during the month of October with the trial and conviction of Sam Bankman-Fried, founder of the cryptocurrency exchange company FTX.

Thoma Bravo has completed its acquisition of NextGen Healthcare, according to a news release.

NextGen, founded in 1994 and based in Atlanta, is a provider of healthcare software services.

Thoma Bravo paid $23.95 for each NextGen share in a transaction valued at approximately $1.8 billion. NextGen has now become a privately held company.

Thoma Bravo…

On this episode of The Corner Series, McGuireWoods’ Geoff Cockrell invites Alessio Baraldi, managing director at Albaron Partners, to discuss value creation in healthcare provider services. Alessio provides insight into the equity structures that work best for his portfolios and how he approaches compensation to keep everyone aligned.“In an environment where there…

GTCR has announced it will acquire Cloudbreak Health from UpHealth for $180 million.

Cloudbreak, based in Columbus, Ohio, is a provider of healthcare-focused language interpretation services. Founded in 2003, the company’s core offering is Martti (My Accessible Real-Time Trusted Interpreter), a video remote interpretation solution designed to connect patients with interpreters in over 250…

A large damage award serves as a significant reminder to file an appearance in a False Claims Act (FCA) case.

In late August of 2022, the Government filed suit against AZ Diabetic and the owner, Hisham Zaghal (Zaghal), in the Eastern District of Virginia, alleging violations under the False Claims Act (FCA), stemming from over $600,000 in reimbursement claims related to prescriptions that AZ Diabetic illegally purchased. After AZ Diabetic failed to file an appearance, the Government moved for default judgment, which was entered by the Court. As a result, AZ Diabetic was liable for just over $12 million in civil penalties and treble damages under the FCA for violations of the Anti-Kickback Statute (AKS).

The Corporate Transparency Act (“CTA”) was enacted in 2021 as part of the Anti-Money Laundering Act of 2020. The CTA requires certain business entities (“Reporting Companies”) to report beneficial ownership information (“BOI”), and, for entities created or registered on or after January 1, 2024, information with respect to any individual who directly files the document creating the Reporting Company (“Company Applicant”), to the U.S. Department of Treasury’s Financial Crimes Enforcement Network (“FinCEN”).

Gauge Capital has announced it has invested in East Coast Institute for Research (ECIR).

ECIR, founded in 2007 and based in Jacksonville, Fla., is a clinical research site management organization focused primarily on the cardiovascular and metabolic therapeutic areas. The company has sites across northern Florida and Georgia.

Gauge, based in Southlake, Texas,…